|
| 37906083 | Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research. | Clin Cancer Res | 2024 |
| 36454580 | Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial. | JAMA Oncol | 2023 |
| 37615099 | Effects of <i>CYP3A4</i> and <i>CYP2C9</i> genotype on systemic anastrozole and fulvestrant concentrations in SWOG S0226. | Pharmacogenomics | 2023 |
| 37693586 | Pre-treatment Amino Acids and Risk of Paclitaxel-induced Peripheral Neuropathy in SWOG S0221. | Res Sq | 2023 |
| 37935109 | Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221. | J Natl Compr Canc Netw | 2023 |
| 37573674 | Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma. | Eur J Cancer | 2023 |
| 37972336 | Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency. | JCO Precis Oncol | 2023 |
| 37673211 | Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials. | Ann Oncol | 2023 |
| 36989609 | Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. | J Clin Oncol | 2023 |
| 37416781 | Ribonuclease 1 Enhances Antitumor Immunity against Breast Cancer by Boosting T cell Activation. | Int J Biol Sci | 2023 |
| 37179362 | Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial. | NPJ Breast Cancer | 2023 |
| 37043123 | Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. | Invest New Drugs | 2023 |
| 36944149 | Novel Prognostic Staging System for Patients With De Novo Metastatic Breast Cancer. | J Clin Oncol | 2023 |
| 37410451 | Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the SWOG S1007 Trial. | JAMA Oncol | 2023 |
| 37377604 | Maternal Embryonic Leucine Zipper Kinase is Associated with Metastasis in Triple-negative Breast Cancer. | Cancer Res Commun | 2023 |
| 37275963 | Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclibâ¿¿+â¿¿endocrine therapy <i>versus</i> endocrine therapy alone in patients with HR+/HER2- early breast cancer. | Ther Adv Med Oncol | 2023 |
| 37140922 | Adherence to Cancer Prevention Lifestyle Recommendations Before, During, and 2 Years After Treatment for High-risk Breast Cancer. | JAMA Netw Open | 2023 |
| 36623515 | Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. | Lancet Oncol | 2023 |
| 36649570 | Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial. | J Clin Oncol | 2023 |
| 36647745 | Thymidine kinase activity levels in serum can identify HR+⿿metastatic breast cancer patients with a low risk of early progression (SWOG S0226). | Biomarkers | 2023 |
| 36634296 | Tumor-Derived Extracellular Vesicles as Complementary Prognostic Factors to Circulating Tumor Cells in Metastatic Breast Cancer. | JCO Precis Oncol | 2023 |
| 36564285 | Corrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis": [Annals of Oncology 33 (2022) 321-329]. | Ann Oncol | 2023 |
| 34844978 | A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-positive Breast Cancer, SWOG S1222. | Clin Cancer Res | 2022 |
| 35507014 | Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. | Clin Cancer Res | 2022 |
| 35347549 | Invasive lobular carcinoma: an understudied emergent subtype of breast cancer. | Breast Cancer Res Treat | 2022 |
| 35902504 | ASO Visual Abstract: Expanding Staging Criteria in T1-2N0 Hormone Receptor-Positive Breast Cancer Patients Enrolled in TAILORx. | Ann Surg Oncol | 2022 |
| 35900648 | Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx. | Ann Surg Oncol | 2022 |
| 36201176 | Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and Misinterpretations. | JAMA Oncol | 2022 |
| 36253486 | Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. | Nat Cancer | 2022 |
| 34954044 | Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. | Ann Oncol | 2022 |
| 35278434 | Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer. | J Biol Chem | 2022 |
| 35175860 | Reply to A. Pfob and C. Sidey-Gibbons. | JCO Clin Cancer Inform | 2022 |
| 35263519 | Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. | N Engl J Med | 2022 |
| 32239145 | Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With Survival. | J Natl Cancer Inst | 2021 |
| 33845027 | Inflammatory breast cancer: early recognition and diagnosis is critical. | Am J Obstet Gynecol | 2021 |
| 33670680 | Cellular Fitness Phenotypes of Cancer Target Genes from Oncobiology to Cancer Therapeutics. | Cells | 2021 |
| 33855973 | TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. | J Clin Invest | 2021 |
| 34914339 | 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. | N Engl J Med | 2021 |
| 34521624 | Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor-Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial. | Clin Cancer Res | 2021 |
| 34725132 | Estrogen Receptor: A Paradigm for Targeted Therapy. | Cancer Res | 2021 |
| 33992718 | Five-Year Longitudinal Analysis of Patient-Reported Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated Versus Hypofractionated Whole-Breast Irradiation. | Int J Radiat Oncol Biol Phys | 2021 |
| 34351787 | Prognostic Model for De Novo and Recurrent Metastatic Breast Cancer. | JCO Clin Cancer Inform | 2021 |
| 34324366 | Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. | J Clin Oncol | 2021 |
| 33986289 | Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation. | Nat Commun | 2021 |
| 34010423 | Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer. | J Natl Cancer Inst | 2021 |
| 34117035 | Association of Cardiovascular Disease Risk Factors with Late Cardiotoxicity and Survival in HER2-positive Breast Cancer Survivors. | Clin Cancer Res | 2021 |
| 34253579 | Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. | Clin Cancer Res | 2021 |
| 32929540 | Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307). | Support Care Cancer | 2021 |
| 32195033 | Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer. | Am J Cancer Res | 2020 |
| 31996688 | Author Correction: CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. | Nat Commun | 2020 |